Upgrading MongoDB to a buy after strong Q1 results, better-than-expected guidance, and a $1 billion buyback program. MDB consistently beats earnings estimates, with Q1 EPS and revenue smashing both consensus and internal guidance. Valuation remains attractive for a high-growth AI software company, with a forward P/E around 40 and P/S near 7.

24/7 Market News: Core Gaming's Newest App Gains Traction as Merger with Siyata Mobile Nears Completion — Neutral
SYTA Newsfile Corp — June 06, 2025Core Gaming's Innovation Engine: AI COMIC and Nowifi Redefine Mobile Experiences Denver, Colorado--(Newsfile Corp. - June 6, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, spotlights the dynamic developments surrounding Siyata Mobile's (NASDAQ: SYTA) $160 million merger with Core Gaming, which is poised to close any day in the second quarter of 2025. Core Gaming's relentless pace of innovation, exemplified by the rapid development and launch of its AI COMIC App and the upcoming Nowifi offline gaming platform, underscores its leadership in AI-driven mobile gaming and creative technologies, positioning …

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing — Neutral
CERO GlobeNewsWire — June 06, 2025SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the “Investors”) pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including …

TotalEnergies: Undervalued, Underappreciated, But Positioned To Outperform — Positive
TTE Seeking Alpha — June 06, 2025TotalEnergies is undervalued despite strong fundamentals, operational resilience, and a credible energy transition strategy, offering a compelling entry point for long-term investors. The company's integrated model across oil, LNG, and renewables ensures cash flow stability, with LNG and integrated power as key growth catalysts for the next decade. Financial discipline, robust free cash flow, and attractive shareholder returns—including a 5.5% dividend yield and buybacks—underscore the stock's appeal versus peers.

Amazon (NASDAQ: AMZN) Stock Price Prediction in 2030: Bull, Bear, & Baseline Forecasts (June 6) — Positive
AMZN 24/7 Wall Street — June 06, 2025Amazon.com Inc. (NASDAQ: AMZN) has been one of the stock market's biggest success stories ever.

Gold market analysis for June 6 - key intra-day price entry levels for active traders — Neutral
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL Kitco — June 06, 2025Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

Tesla Inc. (NASDAQ: TSLA) dropped 14% in a single day yesterday, representing one of its most significant one-day falls in the past few years. The stock currently trades at around $285, significantly down from peaks exceeding $350 in 2024 — resulting in a loss of over $150 billion in market capitalization.

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors — Neutral
CADL GlobeNewsWire — June 06, 2025Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting — Neutral
NVNO Accesswire — June 06, 2025Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of …

Gold News: Fed Rate Cut Bets Rise—Will Weak Payrolls Spark a Gold Rally? — Neutral
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL FXEmpire — June 06, 2025Gold prices hold above key support as traders await NFP data. A weak report could boost Fed cut bets and trigger a gold rally toward $3435 and beyond.

Willis Lease Finance Corporation Announces Pricing of $596.0 Million in Fixed Rate Notes — Neutral
WLFC GlobeNewsWire — June 06, 2025COCONUT CREEK, Fla., June 06, 2025 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, announced today that its wholly-owned subsidiary, Willis Engine Structured Trust VIII (“WEST”), has priced $524,000,000 in aggregate principal amount of Series A Fixed Rate Notes (the “Series A Notes”) and $72,000,000 in aggregate principal amount of Series B Fixed Rate Notes (the “Series B Notes” and, together with the Series A Notes, the “Notes”). The Notes will be secured by, among other things, WEST's direct and indirect interests …

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors — Neutral
CLDX GlobeNewsWire — June 06, 2025HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.

MILWAUKEE, June 06, 2025 (GLOBE NEWSWIRE) -- Douglas Dynamics, Inc. (NYSE: PLOW), North America's premier manufacturer and upfitter of work truck attachments and equipment, today announced that its Board of Directors approved and declared a quarterly cash dividend of $0.295 per share for the second quarter of 2025.

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock — Neutral
AYTU Accesswire — June 06, 2025Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50.

5 ETF Areas That Thrived Amid the Trump-Musk Feud Yesterday — Neutral
TSLA Zacks Investment Research — June 06, 2025TSLA tumbled 14.3% on June 5 as a public clash between Trump and Elon Musk rattled markets and boosted ETFs like TSLZ, SMCZ, AGQ, KORU and MULL on Jun 5.

This stock has seen negative earnings estimate revisions for this year and next.

Streaming giant Netflix (NFLX) has built a 3.5% lead this week alone, thanks to price-target hikes from UBS to $1,450 on Wednesday, and from Jefferies to $1,400 on Tuesday. Out of the gate on Thursday, the shares hit a record high of $1,262.81, bringing its year-to-date tally up to 40%.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference — Neutral
ARQT GlobeNewsWire — June 06, 2025New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0.05% New data demonstrate that for children ages 2 to 5 who achieved disease clearance and switched to proactive twice-weekly application of investigational ZORYVE cream 0.05%, the median duration of disease control was 238 days Consistent efficacy, safety, and tolerability profile observed with ZORYVE cream WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a …

MILLER INDUSTRIES TO PRESENT AND HOST 1X1 INVESTOR MEETINGS AT THE 15TH ANNUAL EAST COAST IDEAS INVESTOR CONFERENCE ON JUNE 11TH & 12TH IN NEW YORK, NY — Neutral
MLR PRNewsWire — June 06, 2025CHATTANOOGA, Tenn. , June 6, 2025 /PRNewswire/ -- Miller Industries, Inc. (NYSE: MLR), the World's Largest Manufacturer of Towing and Recovery Equipment, today announced that Chief Executive Officer, William Miller II, and Chief Financial Officer, Deborah Whitmire, will present at the East Coast IDEAS Investor Conference on Thursday June 12, 2025 at The Westin Times Square in New York, NY.
